Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.43 |
| ▸ | CTSL | P07711 | 7/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847855 | 0.95 | CTSS (0.43) | CTSSCTSLCTSKCTSBKMT2A | |
| SCHEMBL6842993 | 0.95 | CTSS (0.44) | CTSSCTSLCTSKCTSBKMT2A | |
| SCHEMBL14491116 | 0.95 | CTSS (0.44) | CTSSCTSLCTSKCTSBKMT2A | |
| SCHEMBL5471908 | 0.86 | CTSS (0.41) | CTSSCTSLCTSKCTSBTACR2 | |
| SCHEMBL5436195 | 0.84 | CTSS (0.46) | CTSSCTSLCTSKCTSBKMT2A | |
| SCHEMBL6743322 | 0.84 | CTSS (0.46) | CTSSCTSLCTSKCTSBKMT2A | |
| SCHEMBL1987948 | 0.81 | CTSS (0.50) | CTSSCTSLCTSB | |
| SCHEMBL1557679 | 0.81 | CTSS (0.50) | CTSSCTSLCTSB | |
| SCHEMBL5438734 | 0.79 | KMT2A (0.34) | KMT2A | |
| SCHEMBL6063311 | 0.79 | CTSS (0.49) | CTSSCTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSL 11/4885CTSK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.